Adlai Nortye (ANL) Retained Earnings (2022 - 2026)
Adlai Nortye (ANL) posted quarterly Retained Earnings of -$464.8 million for Q4 2025, down 8.28% year-over-year from -$506.8 million in Q4 2024, and down 3.84% quarter-over-quarter from -$447.7 million in Q2 2025.
Analysis
Adlai Nortye (ANL) Retained Earnings (2022 - 2026) Analysis & Trends
Adlai Nortye (ANL) has reported Retained Earnings for 4 consecutive years, with -$464.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Retained Earnings fell 8.28% year-over-year to -$464.8 million; the TTM figure through Dec 2025 stood at -$464.8 million (down 8.28% YoY), while the FY2025 annual figure was -$464.8 million, down 8.28% from the prior year.
- Retained Earnings eased to -$464.8 million in Q4 2025 per ANL's latest filing, from -$447.7 million in the prior quarter.
- Across five years, Retained Earnings topped out at $6.4 million in Q4 2022 and bottomed at -$464.8 million in Q4 2025.
- Historically, Retained Earnings has averaged -$288.6 million across 4 years, with a median of -$415.0 million in 2024.
- Annual changes were most pronounced in 2024 — Retained Earnings tumbled 9857.23% — and 2025, when it fell 8.28%.
- Adlai Nortye's Retained Earnings stood at $6.4 million in 2022, then tumbled by 31.41% to $4.4 million in 2023, then sank by 9857.23% to -$429.3 million in 2024, then dropped by 8.28% to -$464.8 million in 2025.
- Business Quant data shows ANL's Retained Earnings at -$464.8 million in Q4 2025, -$447.7 million in Q2 2025, and -$429.3 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Adlai Nortye | 500.08 Mn | 268.19 Mn | - | -470.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -470.18 Mn |
| Dec 31, 2025 | -464.85 Mn |
| Jun 30, 2025 | -447.65 Mn |
| Dec 31, 2024 | -429.32 Mn |
| Jun 30, 2024 | -400.70 Mn |
| Dec 31, 2023 | 4.40 Mn |
| Dec 31, 2022 | -268.22 Mn |